WLLW vs. CRDL, RX, HLS, SUGR, TGOD, NINE, WMD, MDP, HEXO, and VIR
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), SugarBud Craft Growers (SUGR), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), Medexus Pharmaceuticals (MDP), HEXO (HEXO), and Viridium Pacific Group (VIR). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Willow Biosciences vs. Its Competitors
Willow Biosciences (TSE:WLLW) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
0.1% of Willow Biosciences shares are owned by institutional investors. Comparatively, 11.4% of Cardiol Therapeutics shares are owned by institutional investors. 24.3% of Willow Biosciences shares are owned by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Willow Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Willow Biosciences' net margin of -268.91%. Cardiol Therapeutics' return on equity of -195.07% beat Willow Biosciences' return on equity.
In the previous week, Cardiol Therapeutics had 1 more articles in the media than Willow Biosciences. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for Willow Biosciences. Cardiol Therapeutics' average media sentiment score of 0.67 beat Willow Biosciences' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
Willow Biosciences has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Willow Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Willow Biosciences and Cardiol Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WLLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
This page (TSE:WLLW) was last updated on 7/26/2025 by MarketBeat.com Staff
Free WLLW Stock Alerts